Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 5/2015

01-10-2015

H2Treatment Attenuated Pain Behavior and Cytokine Release Through the HO-1/CO Pathway in a Rat Model of Neuropathic Pain

Authors: Yajun Chen, Hongguang Chen, Keliang Xie, Lingling Liu, Yuan Li, Yonghao Yu, Guolin Wang

Published in: Inflammation | Issue 5/2015

Login to get access

Abstract

Neuropathic pain (NP) is characterized by persistent pain, tactile allodynia, or hyperalgesia. Peripheral nerve injury contributes to rapid progress of inflammatory response and simultaneously generates neuropathic pain. Hydrogen (H2) has anti-inflammation, anti-apoptosis, and anti-oxidative stress effects. Therefore, we hypothesized that H2 treatment could alleviate allodynic and hyperalgesic behaviors and the release of inflammatory factors in rats with neuropathic pain. Peripheral neuropathic pain was established by chronic constriction injury of sciatic nerve in rats. H2 was given twice through intraperitoneal injection at a daily dose of 10 mL/kg during days 1–7 after the operation. Hyperalgesia and allodynia were tested, pro-inflammatory factors of dorsal root ganglia (DRG) and the spinal cord were measured by enzyme-linked immunosorbent assay (ELISA) during days 1–14 after the operation, and heme oxygenase (HO)-1 messenger RNA (mRNA) and protein expression and activities were measured at day 14 after sciatic nerve injury in rats. After Sn (IV) protoporphyrin IX dihydrochloride (SnPP)-IX, hemin, and carbon monoxide-releasing molecule (CORM)-2 had been given for chronic constriction injury (CCI) in rats, the above indicators were assessed. We found that H2 clearly inhibited hyperalgesia and allodynia in neuropathic pain and also attenuated the pro-inflammatory cytokines TNF-α, IL-1β, and high-mobility group box (HMGB) 1. H2 improved HO-1 mRNA and protein expression and activities in the process of pain. SnPP-IX reversed the inhibitory effect of H2 on hyperalgesia and allodynia and on pro-inflammatory cytokines in DRG and the spinal cord. The antinociceptive and anti-inflammatory effects of H2 were involved in the activation of HO-1/CO signaling during neuropathic pain in rats.
Appendix
Available only for authorised users
Literature
1.
Da, S.K., A.F. Paszcuk, G.F. Passos, E.S. Silva, A.F. Bento, and F.C. Meotti. 2011. Activation of cannabinoid receptors by the pentacyclic triterpene alpha, beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain 152: 1872–87.CrossRef
2.
Lavertu, G., S.L. Cote, and Y. de Koninck. 2014. Enhancing K-Cl co-transport restores normal spinothalamic sensory coding in a neuropathic pain model. Brain 137: 724–38.CrossRefPubMed
3.
Bijjem, K.R., S.S. Padi, and S.P. Lal. 2013. Pharmacological activation of heme oxygenase (HO)-1/carbon monoxide pathway prevents the development of peripheral neuropathic pain in Wistar rats. Naunyn-Schmiedeberg’s Archives of Pharmacology 386: 79–90.CrossRefPubMed
4.
Nadeau, S., M. Filali, J. Zhang, B.J. Kerr, S. Rivest, D. Soulet, Y. Iwakura, J.P. de Rivero Vaccari, R.W. Keane, and S. Lacroix. 2011. Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1beta and TNF: implications for neuropathic pain. Journal of Neuroscience 31: 12533–42.CrossRefPubMed
5.
Watkins, L.R., M.R. Hutchinson, E.D. Milligan, and S.F. Maier. 2007. “Listening” and “talking” to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Research Reviews 56: 148–69.PubMedCentralCrossRefPubMed
6.
Verri, W.J., T.M. Cunha, C.A. Parada, S. Poole, F.Q. Cunha, and S.H. Ferreira. 2006. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacology and Therapeutics 112: 116–38.CrossRefPubMed
7.
Scholz, J., and C.J. Woolf. 2007. The neuropathic pain triad: neurons, immune cells and glia. Nature Neuroscience 10: 1361–8.CrossRefPubMed
8.
Vale, M.L., J.B. Marques, C.A. Moreira, F.A. Rocha, S.H. Ferreira, S. Poole, F.Q. Cunha, and R.A. Ribeiro. 2003. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. Journal of Pharmacology and Experimental Therapeutics 304: 102–8.CrossRefPubMed
9.
Fan, W., F. Huang, Z. Wu, X. Zhu, D. Li, and H. He. 2011. Carbon monoxide: a gas that modulates nociception. Journal of Neuroscience Research 89: 802–7.CrossRefPubMed
10.
Rosa, A.O., J. Egea, S. Lorrio, A.I. Rojo, A. Cuadrado, and M.G. Lopez. 2008. Nrf2-mediated haeme oxygenase-1 up-regulation induced by cobalt protoporphyrin has antinociceptive effects against inflammatory pain in the formalin test in mice. Pain 137: 332–9.CrossRefPubMed
11.
Egea, J., A.O. Rosa, S. Lorrio, B.L. Del, A. Cuadrado, and M.G. Lopez. 2009. Haeme oxygenase-1 overexpression via nAChRs and the transcription factor Nrf2 has antinociceptive effects in the formalin test. Pain 146: 75–83.CrossRefPubMed
12.
Maicas, N., M.L. Ferrándiz, I. Devesa, R. Motterlini, M.I. Koenders, W.B. van den Berg, and M.J. Alcaraz. 2010. The CO-releasing molecule CORM-3 protects against articular degradation in the K/BxN serum transfer arthritis model. European Journal of Pharmacology 634: 184–91.CrossRefPubMed
13.
Chen, H.G., K.L. Xie, H.Z. Han, W.N. Wang, D.Q. Liu, G.L. Wang, and Y.H. Yu. 2013. Heme oxygenase-1 mediates the anti-inflammatory effect of molecular hydrogen in LPS-stimulated RAW 264.7 macrophages. International Journal of Surgery 11: 1060–6.CrossRefPubMed
14.
Ohsawa, I., M. Ishikawa, K. Takahashi, M. Watanabe, K. Nishimaki, K. Yamagata, K. Katsura, Y. Katayama, S. Asoh, and S. Ohta. 2007. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine 13: 688–94.CrossRefPubMed
15.
Xie, K., W. Fu, W. Xing, A. Li, H. Chen, H. Han, Y. Yu, and G. Wang. 2012. Combination therapy with molecular hydrogen and hyperoxia in a murine model of polymicrobial sepsis. Shock 38: 656–63.PubMed
16.
Xie, K., Y. Yu, Y. Pei, L. Hou, S. Chen, L. Xiong, and G. Wang. 2010. Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock 34: 90–7.CrossRefPubMed
17.
Xie, K., Y. Yu, Z. Zhang, W. Liu, Y. Pei, L. Xiong, L. Hou, and G. Wang. 2010. Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model. Shock 34: 495–501.CrossRefPubMed
18.
Chen, Q., P. Chen, S. Zhou, X. Yan, J. Zhang, X. Sun, H. Yuan, and W. Yu. 2013. Hydrogen-rich saline attenuated neuropathic pain by reducing oxidative stress. Canadian Journal of Neurological Sciences 40: 857–63.CrossRefPubMed
19.
Bao, Y.H., Q.H. Zhou, R. Chen, H. Xu, L.L. Zeng, X. Zhang, W. Jiang, and D.P. Du. 2014. Gabapentin enhances the morphine anti-nociceptive effect in neuropathic pain via the interleukin-10-heme oxygenase-1 signalling pathway in rats. Journal of Molecular Neuroscience 54: 137–46.PubMedCentralCrossRefPubMed
20.
Bennett, G.J., and Y.K. Xie. 1998. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87–107.CrossRef
21.
Hayashida, K., M. Sano, I. Ohsawa, K. Shinmura, K. Tamaki, K. Kimura, J. Endo, T. Katayama, A. Kawamura, S. Kohsaka, S. Makino, S. Ohta, S. Ogawa, and K. Fukuda. 2008. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochemical and Biophysical Research Communications 373: 30–5.CrossRefPubMed
22.
Chaplan, S.R., F.W. Bach, J.W. Pogrel, J.M. Chung, and T.L. Yaksh. 1994. Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods 53: 55–63.CrossRefPubMed
23.
Bianchi, M., P. Sacerdote, P. Ricciardi-Castagnoli, P. Mantegazza, and A.E. Panerai. 1992. Central effects of tumor necrosis factor alpha and interleukin-1 alpha on nociceptive thresholds and spontaneous locomotor activity. Neuroscience Letters 148: 76–80.CrossRefPubMed
24.
25.
Hervera, A., S. Leanez, R. Motterlini, and O. Pol. 2013. Treatment with carbon monoxide-releasing molecules and an HO-1 inducer enhances the effects and expression of micro-opioid receptors during neuropathic pain. Anesthesiology 118: 1180–97.CrossRefPubMed
26.
Su, L., C. Wang, Y.H. Yu, Y.Y. Ren, K.L. Xie, and G.L. Wang. 2011. Role of TRPM8 in dorsal root ganglion in nerve injury-induced chronic pain. BMC Neuroscience 12: 120.PubMedCentralCrossRefPubMed
27.
28.
Khalil, Z., T. Liu, and R.D. Helme. 1999. Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Pain 79: 31–7.CrossRefPubMed
29.
Zhang, F., X. Feng, R. Dong, H. Wang, J. Liu, W. Li, J. Xu, and B. Yu. 2011. Effects of clonidine on bilateral pain behaviors and inflammatory response in rats under the state of neuropathic pain. Neuroscience Letters 505: 254–9.CrossRefPubMed
30.
DeLeo, J.A., and R.P. Yezierski. 2001. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1–6.CrossRefPubMed
31.
Grace, P.M., P.E. Rolan, and M.R. Hutchinson. 2011. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain, Behavior, and Immunity 25: 1322–32.CrossRefPubMed
32.
Sacerdote, P., S. Franchi, S. Moretti, M. Castelli, P. Procacci, V. Magnaghi, and A.E. Panerai. 2013. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. Journal of Neuroimmune Pharmacology 8: 202–11.CrossRefPubMed
33.
Sacerdote, P., S. Franchi, A.E. Trovato, A.E. Valsecchi, A.E. Panerai, and M. Colleoni. 2008. Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neuroscience Letters 436: 210–3.CrossRefPubMed
34.
Muthuraman, A., and N. Singh. 2012. Neuroprotective effect of saponin rich extract of Acorus calamus L. in rat model of chronic constriction injury (CCI) of sciatic nerve-induced neuropathic pain. Journal of Ethnopharmacology 142: 723–31.CrossRefPubMed
35.
Jaggi, A.S., and N. Singh. 2010. Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. European Journal of Pharmacology 648: 102–9.CrossRefPubMed
36.
Kukkar, A., N. Singh, and A.S. Jaggi. 2013. Neuropathic pain-attenuating potential of aliskiren in chronic constriction injury model in rats. Journal of the Renin-Angiotensin-Aldosterone System 14: 116–23.CrossRefPubMed
37.
Kawasaki, Y., Z.Z. Xu, X. Wang, J.Y. Park, Z.Y. Zhuang, P.H. Tan, Y.J. Gao, K. Roy, G. Corfas, E.H. Lo, and R.R. Ji. 2008. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nature Medicine 14: 331–6.PubMedCentralCrossRefPubMed
38.
Uceyler, N., A. Tscharke, and C. Sommer. 2007. Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain, Behavior, and Immunity 21: 553–60.CrossRefPubMed
39.
Perrin, F.E., S. Lacroix, M. Aviles-Trigueros, and S. David. 2005. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 128: 854–66.CrossRefPubMed
40.
Ruohonen, S., M. Khademi, M. Jagodic, H.S. Taskinen, T. Olsson, and M. Roytta. 2005. Cytokine responses during chronic denervation. Journal of Neuroinflammation 2: 26.PubMedCentralCrossRefPubMed
41.
Kawasaki, Y., L. Zhang, J.K. Cheng, and R.R. Ji. 2008. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. Journal of Neuroscience 28: 5189–94.PubMedCentralCrossRefPubMed
42.
Zhang, R.X., A. Li, B. Liu, L. Wang, K. Ren, H. Zhang, B.M. Berman, and L. Lao. 2008. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 135: 232–239.PubMedCentralCrossRefPubMed
43.
Milligan, E.D., C. Twining, M. Chacur, J. Biedenkapp, K. O’Connor, S. Poole, K. Tracey, D. Martin, S.F. Maier, and L.R. Watkins. 2003. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. Journal of Neuroscience 23: 1026–40.PubMed
44.
Shibasaki, M., M. Sasaki, M. Miura, K. Mizukoshi, H. Ueno, S. Hashimoto, Y. Tanaka, and F. Amaya. 2010. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 149: 514–21.CrossRefPubMed
45.
Tong, W., W. Wang, J. Huang, N. Ren, S.X. Wu, and Y.Q. Li. 2010. Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain. Biochemical and Biophysical Research Communications 395: 572–6.CrossRefPubMed
46.
Lawrence, S., L. Willmott, E. Milligan, S. Winch, B. White, and M. Parker. 2012. Autonomy versus futility? Barriers to good clinical practice in end-of-life care: a Queensland case. Medical Journal of Australia 196: 404–5.CrossRefPubMed
47.
Steiner, A.A., L.G. Branco, F.Q. Cunha, and S.H. Ferreira. 2001. Role of the haeme oxygenase/carbon monoxide pathway in mechanical nociceptor hypersensitivity. British Journal of Pharmacology 132: 1673–82.PubMedCentralCrossRefPubMed
48.
Motterlini, R., J.E. Clark, R. Foresti, P. Sarathchandra, B.E. Mann, and C.J. Green. 2002. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circulation Research 90: E17–E24.CrossRefPubMed
49.
Guillen, M.I., J. Megias, V. Clerigues, F. Gomar, and M.J. Alcaraz. 2008. The CO-releasing molecule CORM-2 is a novel regulator of the inflammatory process in osteoarthritic chondrocytes. Rheumatology (Oxford) 47: 1323–8.CrossRef
Metadata
Title
H2Treatment Attenuated Pain Behavior and Cytokine Release Through the HO-1/CO Pathway in a Rat Model of Neuropathic Pain
Authors
Yajun Chen
Hongguang Chen
Keliang Xie
Lingling Liu
Yuan Li
Yonghao Yu
Guolin Wang
Publication date
01-10-2015
Publisher
Springer US
Published in
Inflammation / Issue 5/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0161-x

Other articles of this Issue 5/2015

Inflammation 5/2015 Go to the issue

OriginalPaper

Systemic Lipopolysaccharide Administration-Induced Cognitive Impairments are Reversed by Erythropoietin Treatment in Mice

OriginalPaper

Alpha-Tomatine Exhibits Anti-inflammatory Activity in Lipopolysaccharide-Activated Macrophages

OriginalPaper

Potential Role of Hepatitis C Virus Alternate Reading Frame Protein in Negative Regulation of T-Bet Gene Expression

OriginalPaper

miR-146a-5p Antagonized AGEs- and P.g-LPS-Induced ABCA1 and ABCG1 Dysregulation in Macrophages via IRAK-1 Downregulation

OriginalPaper

NLRC5 Mediates IL-6 and IL-1β Secretion in LX-2 Cells and Modulated by the NF-κB/Smad3 Pathway

OriginalPaper

The Neuroprotective Effect of Syringic Acid on Spinal Cord Ischemia/Reperfusion Injury in Rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits